Author

Sarika S Deodhar

Observed names: Deodhar, Sarika, Deodhar, Sarika S, Sarika Deodhar, Sarika S. Deodhar

Institution: Biocon (India)

Observed institution: Biocon (India)

ORCID: 0000-0002-4010-8505

Observed ORCID: 0000-0002-4010-8505

OpenAlex ID: A5003248622

Safety, Efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque psoriasis - Results from a randomized phase II trial. (96.13)

2010 · Arun Anand, Deepak Assudani, et al. · The Journal of Immunology · 17

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

2021 · Hope S. Rugo, Eduardo J. Pennella, et al. · Breast Cancer Research and Treatment · 15

Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study

2025 · Jacek C Szepietowski, Adam Reich, et al. · Expert Opinion on Biological Therapy · 7

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

2021 · Hope S. Rugo, Eduardo J. Pennella, et al. · The Breast · 6

Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial

2025 · Jacek C. Szepietowski, Adam Reich, et al. · Expert Opinion on Biological Therapy · 5

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability

2025 · Sarika Deodhar, Subramanian Loganathan, et al. · Advances in Therapy · 5

Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: results from the Study to Test pharmacokinetic BioEquivalence of BiosimiLar ustekinumab to SteLARa (STELLAR-1)

2025 · Jonathan Ackroyd, Sarika S Deodhar, et al. · Expert Opinion on Investigational Drugs · 5

Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis

2026 · Richard Eastell, Eric Orwoll, et al. · JBMR Plus · 2

RE covery and SUR vival of patients with moderate to severe acute RE spiratory distress syndrome (ARDS) due to C OVID-19: a multicenter, single-arm, Phase IV itolizumab T rial: RESURRECT

2023 · Raveendra KR, Chirag Rathod, et al. · Expert Opinion on Biological Therapy · 2

75149 Comparative pharmacokinetics of ustekinumab biosimilar administered via autoinjector or prefilled syringe in healthy subjects

2026 · Elena Wolff-Holz, Dwarkesh Oswal, et al. · Journal of the American Academy of Dermatology

A randomized, double-blind, two-arm, single-dose, parallel study to compare the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Bmab 1000 and originator denosumab in healthy male participants.

2026 · Elena Wolff-Holz, Shrikrishna Kolte, et al. · Journal of Clinical Oncology

60667 Randomized, double-blind, parallel group, multicenter, Phase 3 study to demonstrate equivalent efficacy and to assess safety, immunogenicity and pharmacokinetics of BMAb-1200 compared to reference ustekinumab in adult subjects with moderate to severe chro

2025 · Elena Wolff-Holz, Jacek Szepietowski, et al. · Journal of the American Academy of Dermatology

REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV itolizumab Trial: RESURRECT

2023 · KR, Raveendra, Rathod, Chirag, et al. · Zenodo (CERN European Organization for Nuclear Research)

REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT

2023 · KR, Raveendra, Rathod, Chirag, et al. · Figshare

Works count: 17

Citation count: 64

H-index: 5

I10-index: 2